Search Results - "Voillat, L."

Minor clone provides a reservoir for relapse in multiple myeloma by Magrangeas, F, Avet-Loiseau, H, Gouraud, W, Lodé, L, Decaux, O, Godmer, P, Garderet, L, Voillat, L, Facon, T, Stoppa, A M, Marit, G, Hulin, C, Casassus, P, Tiab, M, Voog, E, Randriamalala, E, Anderson, K C, Moreau, P, Munshi, N C, Minvielle, S

“…Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal…”
Get full text

Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR) by Fornecker, L., Delwail, V., Thieblemont, C., Ghesquieres, H., Bouabdallah, K., Tilly, H., Le Calloch, R., Morschhauser, F., Costello, R., Slama, B., Gyan, E., Chauchet, A., Ngirabacu, M., Durot, E., Choquet, S., Capdupuy, C., Le Goff, M., Voillat, L., Snauwaert, S., Amorim, S.

Get full text

Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group by Carras, S., Torroja, A., Emadali, A., Daguindau, N., Tempescul, A., Macro, M., Moreau, A., Tchernonog, E., Houot, R., Schmitt, A., Dartigeas, C., Dupuis, J., Jardin, F., Banos, A., Corm, S., Barbieux, S., Zerazhi, H., Arkam, Y., Fouillet, L., Fontan, J., Vilque, J., Moles, M., Sarkozy, C., Morineau, N., Joly, B., Voillat, L., Alexis, M., Fornecker, L. M., Garidi, R., Amorim, S., Bouabdallah, K., Dorvaux, V., Chabrot, C., Feugier, P., Damaj, G., Fleury, J., Delwail, V., Ysebaert, L., Burroni, B., Callanan, M., Legouill, S., Gressin, R.

Get full text

BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL by Lemonnier, F., Safar, V., Ferchiou, A., Cottereau, A., Bachy, E., Cartron, G., Moles‐Moreau, M., Delmer, A., Bouabdallah, R., Voillat, L., Parrens, M., Casasnovas, O., Cacheux, V., Réguy, C., Tilly, H., Meignan, M., Gaulard, P., Leval, L., Delfau‐Larrue, M., Haioun, C.

Get full text

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE by Schavgoulidze, A., Perrot, A., Cazaubiel, T., Leleu, X., Manier, S., Buisson, L., Maheo, S., Do Souto Ferreira, L., Lannes, R., Pavageau, L., Hulin, C., Marolleau, J.‐P., Voillat, L., Belhadj, K., Divoux, M., Slama, B., Brechignac, S., Macro, M., Stoppa, A.‐M., Sanhes, L., Orsini‐Piocelle, F., Fontan, J., Chretien, M.‐L., Demarquette, H., Mohty, M., Avet‐Loiseau, H., Corre, J.

Get full text

High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study by Mannone, L., Gardin, C., Quarre, M. C., Bernard, J. F., Vassilieff, D., Ades, L., Park, S., Vaultier, S., Hamza, F., Beyne‐rauzy, M. O., Cheze, S., Giraudier, S., Agape, P., Legros, L., Voillat, L., Dreyfus, F., Fenaux, P.

“…Summary An open‐label, phase II non‐randomised trial was conducted with darbepoetin (DAR), an erythropoiesis‐stimulating factor with prolonged half‐life, at a…”
Get full text

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma by Limat, S., Demesmay, K., Voillat, L., Bernard, Y., Deconinck, E., Brion, A., Sabbah, A., Woronoff-Lemsi, M. C., Cahn, J. Y.

“…Background: To determine the incidence of early cardiotoxicity induced by the CHOP regimen in patients with aggressive non-Hodgkin’s lymphoma (NHL) and to…”
Get full text

PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL by Canioni, D., Brice, P., Bologna, S., Voillat, L., Gabarre, J., Casasnovas, O., Devidas, A., Coiffier, B., Aoudjhane, A., Audouy, B., Andre, M., Fortpied, C., Carde, P., Mounier, N., Briere, J.

Get full text

Rituximab in CD20 positive multiple myeloma by Moreau, P, Voillat, L, Benboukher, L, Mathiot, C, Dumontet, C, Robillard, N, Hérault, O, Garnache, F, Garand, R, Varoqueaux, N, Avet-Loiseau, H, Harousseau, J L, Bataille, R

Get full text

The Treatment (Tx) of Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: A Systematic Literature Review and Network Meta-Analysis by Weisel, K, Doyen, C, Dimopoulos, M.A, Yee, A, Kropff, M, Lahuerta, J.J, Martin, A, Travers, K, Abildgaard, N, Lu, J, Van Droogenbroeck, J, Geraldes, C, Petrini, M, Voillat, L, Vilque, J.P, Voog, E, Facon, T

Get full text

MELPHALAN-PREDNISONE-THALIDOMIDE (MP-T) DEMONSTRATES A SIGNIFICANT SURVIVAL ADVANTAGE IN ELDERLY PATIENTS >75 YEARS WITH MULTIPLE MYELOMA COMPARED WITH MELPHALAN-PREDNISONE (MP) IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, IFM01/01 by Hulin, C, Decaux, O, Coiteux, V, Rodon, P, Pegourie, B, Benboubker, L, Gagneux, L, Dib, M, Voillat, L, Guillerm, G, Moreau, P

Get full text

Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma by Limat, S., Demesmay, K., Voillat, L., Bernard, Y., Deconinck, E., Brion, A., Sabbah, A., Woronoff-Lemsi, M.C., Cahn, J.Y.

Get full text

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? by Chretien, Marie-Lorraine, Corre, Jill, Lauwers-Cances, Valerie, Magrangeas, Florence, Cleynen, Alice, Yon, Edwige, Hulin, Cyrille, Leleu, Xavier, Orsini-Piocelle, Frederique, Blade, Jean-Sebastien, Sohn, Claudine, Karlin, Lionel, Delbrel, Xavier, Hebraud, Benjamin, Roussel, Murielle, Marit, Gerald, Garderet, Laurent, Mohty, Mohamad, Rodon, Philippe, Voillat, Laurent, Royer, Bruno, Jaccard, Arnaud, Belhadj, Karim, Fontan, Jean, Caillot, Denis, Stoppa, Anne-Marie, Attal, Michel, Facon, Thierry, Moreau, Philippe, Minvielle, Stephane, Avet-Loiseau, Hervé

“…The prognosis of multiple myeloma is mainly dependent upon chromosomal changes. The 2 major abnormalities driving poor outcome are del(17p) and t(4;14)…”
Get full text

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience by Hebraud, Benjamin, Magrangeas, Florence, Cleynen, Alice, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Hulin, Cyrille, Leleu, Xavier, Yon, Edwige, Marit, Gerald, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Belhadj, Karim, Voillat, Laurent, Garderet, Laurent, Macro, Margaret, Caillot, Denis, Mohty, Mohamad, Facon, Thierry, Moreau, Philippe, Attal, Michel, Munshi, Nikhil, Corre, Jill, Minvielle, Stephane, Avet-Loiseau, Herve

“…In multiple myeloma, cytogenetic changes are important predictors of patient outcome. In this setting, the most important changes are deletion 17p, del(17p),…”
Get full text

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma by Attal, Michel, Harousseau, Jean-Luc, Leyvraz, Serge, Doyen, Chantal, Hulin, Cyrille, Benboubker, Lofti, Agha, Ibrahim Yakoub, Bourhis, Jean-Henri, Garderet, Laurent, Pegourie, Brigitte, Dumontet, Charles, Renaud, Marc, Voillat, Laurent, Berthou, Christian, Marit, Gerald, Monconduit, Mathieu, Caillot, Denis, Grobois, Bernard, Avet-Loiseau, Herve, Moreau, Philippe, Facon, Thierry, for the Inter-Groupe Francophone du Myélome (IFM)

“…Newer chemotherapeutic protocols as well as high-dose chemotherapy have increased the response rate in myeloma. However, these treatments are not curative…”
Get full text

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial by Mounier, N., Brice, P., Bologna, S., Briere, J., Gaillard, I., Heczko, M., Gabarre, J., Casasnovas, O., Jaubert, J., Colin, P., Delmer, A., Devidas, A., Bachy, E., Nicolas-Virelizier, E., Aoudjhane, A., Humbrecht, C., Andre, M., Carde, P.

“…Treatment with escalated BEACOPP achieved a superior time to treatment failure over ABVD in patients with disseminated Hodgkin lymphoma. However, recent…”
Get full text

Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study by MOREAU, P, MILPIED, N, HAROUSSEAU, J. L, VOILLAT, L, COLOMBAT, P, MAHE, B, RAPP, M. J, MOREAU, A, DUPAS, B, BULABOIS, C. E, JUGE-MORINEAU, N

“…The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT)…”
Get full text

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma by Attal, Michel, Harousseau, Jean-Luc, Facon, Thierry, Guilhot, François, Doyen, Chantal, Fuzibet, Jean-Gabriel, Monconduit, Mathieu, Hulin, Cyrille, Caillot, Denis, Bouabdallah, Reda, Voillat, Laurent, Sotto, Jean-Jacques, Grosbois, Bernard, Bataille, Regis

“…This investigation of the treatment of multiple myeloma compared one cycle of high-dose chemotherapy plus a single autologous stem-cell transplantation with…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Fornecker, L, Delwail, V, Thieblemont, C, Ghesquieres, H, Bouabdallah, K, Tilly, H, Le Calloch, R, Morschhauser, F, Costello, R, Slama, B, Gyan, E, Chauchet, A, Ngirabacu, M, Durot, E, Choquet, S, Capdupuy, C, Le Goff, M, Voillat, L, Snauwaert, S, Amorim, S

Get full text

Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease : retrospective analysis of 158 cases from the French registry by MOREAU, P, FLEURY, J, LAMY, T, LOTZ, J. P, MUNCK, J. N, DIVINE, M, FERME, C, PENY, A. M, FRUCHART, C, ORIOL, P, OJEDA, M, REMAN, O, BRICE, P, MILPIED, N, GISSELBRECHT, C, LEGROS, M, HAROUSSEAU, J. L, COLOMBAT, P, BOUABDALLAH, R, LIOURE, B, VOILLAT, L, CASASNOVAS, O, FRANCOIS, S, SADOUN, A

“…This retrospective study was undertaken to evaluate cure rates, toxicity and late effects of early intensive therapy followed by autologous stem cell…”
Get full text